Negative-Control Outcomes for Detecting Hidden Bias

Why Examine an Outcome the Treatment Cannot Cause?

In an observational study, measured covariates may not remove all confounding. A useful diagnostic is to examine whether treatment is associated with an outcome that the treatment could not have caused. If an adjusted association remains, it can reveal that treatment groups differ in ways not captured by the adjustment set. The diagnostic is informative only when the chosen outcome and study design meet substantive assumptions; it is not a direct estimate of bias in the main treatment effect.

For example, suppose a study estimates the effect of a medication on a later clinical outcome. A carefully chosen measurement recorded before treatment began cannot be caused by that medication. If it nevertheless differs between treated and untreated patients after adjustment, the difference may signal residual confounding, treatment selection, or another source of bias. The finding warrants investigation, but does not by itself identify which explanation is correct.

Definition: Let \(A\) be a binary treatment, \(Y\) the study outcome, and \(X\) the measured covariates used for adjustment. A negative-control outcome, written \(Y^{NC}\), is an outcome for which the treatment has no causal effect: \(Y^{NC}(1)=Y^{NC}(0)\) for every unit, or for the target population under consideration. It is selected because causes or data-generating processes relevant to \(Y\) are also expected to affect \(Y^{NC}\). For the outcome to diagnose confounding of the treatment effect, those processes must also be associated with treatment after adjustment for \(X\).

The potential-outcomes condition means that changing treatment alone would not change the negative-control outcome. It is stronger than saying that a treatment effect seems unlikely or is not statistically significant. A negative control is not simply an unrelated outcome: if it shares no relevant causes or bias mechanisms with the study outcome, its treatment association may say little about confounding of the study effect.

What an Association Can Reveal

Let \(U\) represent an unmeasured factor that influences treatment choice and both outcomes. If adjustment for \(X\) does not eliminate the association between \(A\) and \(U\), then \(A\) can remain associated with \(Y^{NC}\), even though it cannot cause \(Y^{NC}\). That residual association is a warning that the treatment groups may remain systematically different. The same hidden factor may also confound the association between \(A\) and \(Y\).

A common diagnostic estimates the conditional association between treatment and negative-control outcome given \(X\). In a linear model, the coefficient of \(A\) is a concise measure of that association. The model below describes the diagnostic; it does not make a causal effect of treatment on \(Y^{NC}\) possible when the negative-control assumption is true.

Diagnostic model: For a continuous negative-control outcome, fit \(Y^{NC}=\beta_0+\beta_A A+\beta_X^\mathsf{T}X+\varepsilon\), with an appropriate standard-error method for the sampling design. Under a correctly specified adjustment model, adequate overlap in treatment across \(X\), and the assumption that treatment has no effect on \(Y^{NC}\), a nonzero \(\beta_A\) indicates a conditional association that needs explanation. It is evidence of a possible design or adjustment problem, not proof that unmeasured confounding caused the association.

The simple omitted-confounder calculation makes the signal’s logic explicit. Suppose the variables have been residualized with respect to \(X\), and denote residuals by tildes. In this simplified linear model, let \(\widetilde{Y}^{NC}=\gamma\widetilde{U}+\widetilde{\varepsilon}\), where \(\widetilde{\varepsilon}\) is uncorrelated with \(\widetilde{A}\). The coefficient from regressing the residualized negative-control outcome on residualized treatment is the covariance of those residuals divided by the variance of residualized treatment.

\begin{aligned} \beta_A^{NC} &= \frac{\operatorname{Cov}(\widetilde{A},\widetilde{Y}^{NC})} {\operatorname{Var}(\widetilde{A})}\\ &= \frac{\operatorname{Cov}(\widetilde{A}, \gamma\widetilde{U}+\widetilde{\varepsilon})} {\operatorname{Var}(\widetilde{A})}\\ &= \gamma \frac{\operatorname{Cov}(\widetilde{A},\widetilde{U})} {\operatorname{Var}(\widetilde{A})}. \end{aligned}

The last equality follows because \(\operatorname{Cov}(\widetilde{A},\widetilde{\varepsilon})=0\). Thus, if \(U\) still predicts treatment after adjustment and affects the negative-control outcome (\(\operatorname{Cov}(\widetilde{A},\widetilde{U})\ne 0\) and \(\gamma\ne 0\)), the adjusted treatment coefficient need not be zero. Conversely, the coefficient can be zero if \(U\) does not affect the negative control, if it is no longer associated with treatment after adjustment, or if multiple contributions cancel. A null result therefore cannot rule out hidden bias in the study outcome.

Assumptions Behind the Comparison

A negative-control diagnostic is only as credible as its design assumptions. Before interpreting an estimate, state why the selected outcome qualifies and what the adjusted comparison represents.

No causal effect of treatment: Treatment cannot affect \(Y^{NC}\), directly or through downstream pathways, over the relevant time period. A plausible story is not enough if treatment could change care, behavior, measurement, or follow-up that affects the control outcome.
Relevant shared causes or bias mechanisms: The negative control should respond to at least some causes that matter for the study outcome, and residual differences in those causes should be able to produce a treatment association. Merely sharing a broad label, such as “health status,” does not ensure this.
Comparable target and measurement: The same study population, treatment definition, covariate adjustment, and observation process should be used where appropriate. Differential recording or missingness can create an association that is not a confounding signal.
Adequate adjustment and overlap for the reported comparison: The model should represent the intended conditional comparison, with sufficient treated and untreated observations across covariate patterns. Poor overlap or model misspecification can distort the diagnostic just as it can distort other adjusted comparisons.

These conditions do not imply that the association with \(Y^{NC}\) must have the same direction or magnitude as confounding bias in \(Y\). The two outcomes can respond differently to a hidden cause. In particular, an observed negative-control association is not a conversion factor that can simply be subtracted from the study estimate. Quantifying bias from negative controls requires additional assumptions beyond using one to detect a warning signal.

Worked Example: A Residual Association With a Clinical Marker

Hypothetical data. Investigators study a medication’s effect on a later clinical outcome. They use a continuous laboratory marker recorded at the start of follow-up as \(Y^{NC}\), arguing that the medication has no effect on this marker at that time. After adjusting for age, baseline severity, and clinic, a linear regression gives \(\hat{\beta}_A=2.40\) marker units and \(SE=0.80\) units. Assume the model is appropriate, the sample is large enough for a normal approximation, and the marker is genuinely unaffected by treatment.

The test statistic for no adjusted association is \(z=\hat{\beta}_A/SE\). Substitution gives \(z=2.40/0.80=3.00\). Under the null and the stated approximation, the two-sided p-value is about \(0.0027\). A 95% confidence interval is calculated as estimate plus or minus \(1.96\) standard errors:

2.40 \pm 1.96(0.80) = 2.40 \pm 1.568 = (0.832,\ 3.968)\text{ marker units}.

The adjusted association is statistically distinguishable from zero under this model. Because treatment cannot cause the marker, this is a warning that adjustment may have left residual differences or that another assumption, such as comparable measurement, has failed. It does not establish which bias mechanism is responsible, nor does it show that the medication’s estimated effect on the later clinical outcome is biased upward by 2.40 units.

Read the Diagnostic in Context

A large estimated association can be a useful alarm, but a small or imprecise estimate is not reassurance that all confounding has been removed. The diagnostic has limited power when the negative-control outcome is measured noisily, is only weakly affected by relevant confounders, or is measured in a small sample. It can also fail when the unmeasured causes of treatment and \(Y\) differ from those that affect \(Y^{NC}\).

For a binary negative-control outcome, the same conceptual comparison applies, but the reported scale should be clear. A risk difference, risk ratio, or odds ratio answers a different numerical question. The model and uncertainty calculation must fit the outcome, sampling design, and adjustment strategy. The next example uses an unadjusted risk difference only to illustrate how an imprecise result should be read; it does not claim that crude groups are exchangeable.

Worked Example: A Small, Uncertain Difference in a Rare Outcome

Hypothetical data. In two treatment groups, a binary negative-control outcome is observed in 60 of 10,000 treated patients and 50 of 10,000 untreated patients. Assume independent binomial samples for this calculation. The unadjusted risks are \(60/10{,}000=0.0060\) and \(50/10{,}000=0.0050\), so the estimated risk difference is \(0.0010\), or 1.0 event per 1,000 patients.

For independent groups, the estimated standard error of the risk difference is the square root of the sum of the estimated binomial variances:

SE = \sqrt{\frac{0.0060(1-0.0060)}{10{,}000} +\frac{0.0050(1-0.0050)}{10{,}000}} = \sqrt{1.094\times 10^{-6}} \approx 0.001046.

The normal-approximation statistic is \(z=0.0010/0.001046\approx0.956\), with a two-sided p-value of about \(0.34\). The 95% interval is \(0.0010\pm1.96(0.001046)\), or approximately \((-0.00105,\ 0.00305)\). In context, the data are compatible with a risk difference from about 1.05 fewer to 3.05 more events per 1,000 treated patients. This crude comparison does not show a statistically clear association, but it does not establish that the treatment groups are free of hidden bias. Adjustment and the study design would also need scrutiny.

Worked Example: A Pre-Treatment Outcome as a Negative Control

Hypothetical data. In an observational study of treatment for a chronic condition, researchers compare a symptom score recorded before treatment began. A later treatment cannot cause a genuinely pre-treatment score, so the score may serve as a negative-control outcome. After adjustment for age and clinic, the estimated treated-minus-untreated difference is \(1.70\) points, with \(SE=0.30\) points. Assume a correctly specified linear comparison and a large-sample normal approximation.

The standardized statistic is \(z=1.70/0.30=5.67\). A 95% interval is \(1.70\pm1.96(0.30)=1.70\pm0.588\), giving \((1.112,\ 2.288)\) points. The adjusted pre-treatment score is therefore higher by an estimated 1.70 points in the treated group, with an interval that excludes zero under the model.

Since treatment occurs after the score was recorded, the difference cannot be an effect of that later treatment. It suggests that treated and untreated patients differed before treatment, possibly because baseline severity influenced treatment choice and also predicts the later study outcome. Other explanations remain possible, including selection into the study or an error in the recorded timing. The finding is a reason to investigate those possibilities, not a numerical estimate of confounding in the treatment effect.

Common Mistake: Treating a Null Result as Validation

Wrong reasoning: “The negative-control association was not statistically significant, so there cannot be residual confounding.” A p-value above a chosen threshold does not show that the association is zero, and even a precisely estimated zero association with one negative control does not exclude hidden causes that affect the study outcome but not that control.

Correction: Report the estimate and its uncertainty, then ask whether the interval rules out associations large enough to matter for the diagnostic. Also assess whether the negative control is sensitive to the particular confounding mechanisms of concern. A null or imprecise diagnostic is limited evidence, not proof of no bias. Likewise, a nonzero association is a warning, not proof that a specific unmeasured confounder is present.

Key takeaway: A negative-control outcome is useful when treatment cannot cause it but residual causes or bias processes relevant to the study outcome can also produce a treatment association with it. An association raises concern; a null result does not certify exchangeability, and neither result alone quantifies bias in the main causal effect.

Check Your Understanding

Answer each question by distinguishing the diagnostic association from the causal effect of interest.

What potential-outcomes condition defines a negative-control outcome for a binary treatment?
Why is it not enough for a negative-control outcome to be unaffected by treatment? What further connection to the study outcome and treatment assignment is needed?
In the omitted-confounder derivation, what two conditions make the residualized treatment coefficient on the negative-control outcome nonzero?
A negative-control estimate is close to zero but has a wide confidence interval. What can and cannot be concluded?
Why would a pre-treatment measurement be an invalid negative control if treatment assignment could change whether that measurement is recorded?
Why should a nonzero negative-control association not simply be subtracted from the estimated effect on the study outcome?